Peer-Review
Evidence-Based Reporting With Peer-Reviewed Integrity
In a world filled with anonymous web postings, impromptu blogs, and hurried articles which can compromise important medical news, physicians need to be able to rely on an authoritative source to learn about the pivotal advances in clinical practice which take place during medical congresses.
MD Conference Online is the first publication to put conference ‘news’ to the rigorous test of peer-review. Primary source data drives our evidence based reporting. The news you read has been vetted, tested and thoroughly challenged by the very faculty who presented at the live congress.
 |
Official Peer-Reviewed Highlights from the |
ACC.11
60th Annual Scientific Session and i2 Summit 2011
Is It Time for Antiplatelet Therapy to Enter Personalized Medicine?
Since its approval in 1997, clopidogrel has been a cornerstone of therapy in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI) to reduce future ischemic events. Although the drug has led to significantly better outcomes, high variability in the antiplatelet effect has been demonstrated. A number of factors are responsible for this variability as demonstrated through pharmacodynamic and pharmacokinetic studies, including clinical factors and the presence of CYP2C19 loss-of-function alleles and reduced metabolism of clopidogrel to its active metabolite leading to attenuation of the intended anti-platelet effect [Brandt JT et al. J Thromb Haemost 2007]. See summary: Is It Time for Antiplatelet Therapy to Enter Personalized Medicine?